The University of Hong Kong (HKU) has invented a patented technology called “Flow-through hybridization”, and licensed it to Guangdong Hybribio Biotech Co., Ltd. A low density medical gene chip working platform, HybriMax, was developed based on the patented technology and further collaboration between HKU and Hybribio. HybriMax is the core system for future diagnostic kits produced by the same company.

HybriMax is an all-in-one integrated polymerase chain reaction (PCR), hybridization, and gene chip processing system based on HKU’s Flow-Through hybridization technology which allows analyzing nucleic acid in patient samples in a faster, simpler, and more economic manner.

After over ten years of development, Hybribio developed an automatic nucleic acid molecular diagnostic platform, and introduced 21 Human papillomavirus (HPV) GenoArray Diagnostic kit, 37 HPV GenoArray Diagnostic kit, α,β-THAL Detection Kit, sexually transmitted disease (STD) Detection Kits, Deaf gene diagnostic kit to the market. These kits have been approved by China Food and Drug Administration (CFDA) and obtained European Conformity In Vitro Diagnostics (CE IVD) licenses, and have been extensively used in medical and research laboratories in European and Asian countries such as Spain, Turkey, China, Japan, Thailand and The Philippines. More than 2 million tests have applied the technology with sound feedback. Currently, more than 1,200 hospitals and medical institutes in China have adopted this HPV diagnostic technology and about 1,000 medical organizations in more than 20 countries around the globe have been using its products for clinical and research purposes. This flow-through hybridization platform along with HPV diagnostic kit series has been performed in over 15 million women and prevented hundreds and thousands of women from developing cervical cancer, a major malignancy in women health.

For more information, please visit : https://www.hku.hk/press/news_detail_16912.html